VacciMonitor (Nov 2015)

Evaluation of monoclonal antibodies to the capsular polysaccharide of Neisseria meningitidis serogroups A, C, Y, W and X to be used in the identity assays

  • Osmir Cabrera-Blanco,
  • Fidel Ramírez-Bencomo,
  • Abel Fajardo-Sánchez,
  • Aleida Mandariote-Llanes,
  • Maribel Cuello-Pérez

Journal volume & issue
Vol. 24, no. 2
pp. 64 – 70

Abstract

Read online

Neisseria meningitidis serogroups A, B, C, W, Y and X are the main responsible of meningococcal disease. Vaccines are necessary to prevent this disease. The Finlay Institute is developing polysaccharide vaccines against serogroups A, C, W, Y and X. In the development of vaccines, the identity assay is a mandatory requirement for final product release. This test is performed by Dot Blot technique using commercial polyclonal antibodies (PAb). However, the Finlay Institute has monoclonal antibodies (mAbs) against capsular polysaccharides from N. meningitidis (CPs). The objective of this work was to use these mAbs in identity tests to replace commercial PAb. The specificity of the mAbs, the cross-reactivity with other CPs and the identity of the CPs present in four multivalent polysaccharide vaccines, were evaluated. All tested mAbs showed high specificity, and no cross-reactivity was found. Also all mAbs were able to identify the presence of homologous PsC in multivalent vaccine formulations. We conclude that the mAbs obtained in our institution can be used for identity assays of vaccines

Keywords